Sophia Genetics SA Partners with Tyrolpath to Launch MSK-IMPACT Flex in Austria
I'm PortAI, I can summarize articles.
Sophia Genetics SA has partnered with Tyrolpath to introduce MSK-IMPACT Flex in Austria, marking the first adoption of this advanced oncology solution in the country. This collaboration aims to enhance cancer testing and precision oncology by leveraging the SOPHiA DDM Platform for comprehensive genomic profiling of solid tumors, addressing the need for actionable genomic insights in cancer care.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments